Global Acute Lymphoblastic Leukemia (ALL) Clinical Landscape Market Report 2021-2027
DUBLIN, June 21, 2021 /PRNewswire/ -- The "Market Spotlight: Acute Lymphoblastic Leukemia (ALL)" report has been added to ResearchAndMarkets.com's offering.
This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
The report estimates that in 2018, there were 86,600 incident cases of acute lymphoblastic leukemia (ALL) worldwide, and expects that number to increase to 93,500 incident cases by 2027.
Approved drugs in the ALL space focus on a wide variety of targets. The majority of these therapies are administered via the intravenous route, with the remaining products being available in oral and intramuscular formulations.
The highest proportion of industry-sponsored drugs in active clinical development for ALL are in Phase I, with only one drug in the NDA/BLA phase.
Therapies in development for ALL focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the intravenous route, with the remainder being oral and intramuscular formulations.
High-impact upcoming events for drugs in the ALL space comprise topline Phase II trial results for Sarclisa, and an expected supplemental BLA filing for Tecartus.
The overall likelihood of approval of a Phase I hematologic asset is 8.7%, and the average probability a drug advances from Phase III is 58.9%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for ALL have been in the early and midphases of development, with 92% of trials in Phase I-II, and only 8% in Phase III-IV.
The US has a substantial lead in the number of ALL clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
Novartis has the highest number of completed clinical trials for ALL, with 47 trials.
Novartis also leads industry sponsors with the highest overall number of clinical trials for ALL
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
- Definition
- Patient segmentation
- Symptoms
- Risk factors
- Diagnosis
TREATMENT
- Chemotherapy
- Corticosteroids
- TKI therapy
- Immunotherapy
- Radiation therapy
- Stem cell transplant
EPIDEMIOLOGY
MARKETED DRUGS
PIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
- Blincyto for ALL (December 10, 2019)
- GC022 for ALL (December 7, 2019)
- Blincyto for ALL (September 24, 2019)
KEY UPCOMING EVENTS
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
- ADC Therapeutics In Asia JV, License Deal With Overland
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
- Sponsors by status
- Sponsors by phase
BIBLIOGRAPHY
- Prescription information
APPENDIX
LIST OF FIGURES
Figure 1: Trends in incident cases of ALL, 2018-27
Figure 2: Overview of pipeline drugs for ALL in the US
Figure 3: Pipeline drugs for ALL, by company
Figure 4: Pipeline drugs for ALL, by drug type
Figure 5: Pipeline drugs for ALL, by classification
Figure 6: Blincyto for ALL (September 24, 2019): Phase III - Pediatric (1st Relapse)
Figure 7: Key upcoming events in ALL
Figure 8: Probability of success in the hematologic pipeline
Figure 9: Clinical trials in ALL
Figure 10: Top 10 drugs for clinical trials in ALL
Figure 11: Top 10 companies for clinical trials in ALL
Figure 12: Trial locations in ALL
Figure 13: ALL trials status
Figure 14: ALL trials sponsors, by phase
LIST OF TABLES
Table 1: Incident cases of ALL, 2018-27
Table 2: Marketed drugs for ALL
Table 3: Pipeline drugs for ALL in the US
Table 4: Blincyto for ALL (December 10, 2019)
Table 5: GC022 for ALL (December 7, 2019)
Table 6: Blincyto for ALL (September 24, 2019)
Table 7: Historical global sales, by drug ($m), 2015-19
Table 8: Forecasted global sales, by drug ($m), 2021-25
Companies Mentioned
- Fate Therapeutics
- Novartis
- Ono Pharmaceutical
For more information about this report visit https://www.researchandmarkets.com/r/2xfnfk
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article